[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Health Agencies Update
August 18, 1999

Shingles Vaccine Trial

Author Affiliations

Not Available

Not Available

JAMA. 1999;282(7):625. doi:10.1001/jama.282.7.625-JHA90006-4-1

Researchers at the NIAID launched a phase 3 multicenter trial of an experimental shingles vaccine. The vaccine is a more potent version of the chickenpox vaccine already in use to prevent varicella zoster virus (VZV) infection in children.

Researchers believe that the vaccine may be able to prevent shingles by boosting the body's immune response to VZV infection in a person who had chickenpox in childhood. The national trial, which will involve some 20 medical centers, is recruiting 37,000 volunteers. To be eligible for the trial, participants must be age 60 or older, have had chickenpox, have never had shingles, and be in good general health. For further information about the trial, call (800) 772-5464, ext 658.

First Page Preview View Large
First page PDF preview
First page PDF preview